Fennec Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Fennec Pharmaceuticals
FENC Stock  USD 7.70  0.06  0.77%   
Fennec Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Fennec Pharmaceuticals' valuation are provided below:
Gross Profit
36.1 M
Profit Margin
(0.18)
Market Capitalization
265 M
Enterprise Value Revenue
6.761
Revenue
38.8 M
We have found one hundred twenty available fundamental signals for Fennec Pharmaceuticals, which can be analyzed and compared to other ratios and to its rivals. Investors should ensure to verify all of Fennec Pharmaceuticals' prevailing performance against the performance from 2010 to 2026 to make sure the company is sustainable down the road.

Fennec Pharmaceuticals Total Revenue

49.91 Million

Check Fennec Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Fennec Pharmaceuticals' main balance sheet or income statement drivers, such as Discontinued Operations of 0.0, Depreciation And Amortization of 760 K or Interest Expense of 4.3 M, as well as many indicators such as Price To Sales Ratio of 3.45, Dividend Yield of 0.0 or Days Sales Outstanding of 93.98. Fennec financial statements analysis is a perfect complement when working with Fennec Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Fennec Stock
Check out the analysis of Fennec Pharmaceuticals Correlation against competitors.
For information on how to trade Fennec Stock refer to our How to Trade Fennec Stock guide.

Fennec Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets47.2 M44.9 M17.7 M
Slightly volatile
Short and Long Term Debt Total14.7 M19.3 M9.1 M
Slightly volatile
Other Current Liabilities3.9 M3.7 M2.1 M
Very volatile
Total Current Liabilities7.3 M6.9 M3.4 M
Slightly volatile
Other Liabilities284.1 K299 K3.5 M
Slightly volatile
Property Plant And Equipment Net552.5 K484.1 K419.8 K
Slightly volatile
Accounts Payable3.4 M3.2 M1.3 M
Slightly volatile
Cash28 M26.6 M14 M
Slightly volatile
Cash And Short Term Investments28 M26.6 M14 M
Slightly volatile
Common Stock Shares Outstanding28.7 M27.3 M17.1 M
Slightly volatile
Liabilities And Stockholders Equity47.2 M44.9 M17.7 M
Slightly volatile
Non Current Liabilities Total46.1 M43.9 M9.9 M
Slightly volatile
Other Current Assets3.7 M3.5 M829.9 K
Slightly volatile
Other Stockholder Equity47.6 M67 M45.6 M
Slightly volatile
Total Liabilities53.4 M50.8 M12.9 M
Slightly volatile
Property Plant And Equipment Gross552.5 K484.1 K419.8 K
Slightly volatile
Total Current Assets46.3 M44.1 M17.5 M
Slightly volatile
Short Term Debt1.9 K2 K644.3 K
Slightly volatile
Common Stock83.1 M145.6 M95.4 M
Slightly volatile
Capital Surpluse49.4 M61.2 M46.2 M
Slightly volatile
Net Invested Capital16.5 M13.5 M23 M
Slightly volatile
Net Working Capital25.9 M37.2 M25.1 M
Pretty Stable
Capital Stock145.6 M145.6 M120.2 M
Slightly volatile
Long Term Debt Total4 M4.5 M4.9 M
Slightly volatile

Fennec Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative24.2 M23.1 M8.8 M
Slightly volatile
Other Operating Expenses47.2 M45 M14.6 M
Slightly volatile
Research Development291.6 K307 K2.1 M
Pretty Stable
Total Operating Expenses43.9 M41.8 M14.1 M
Slightly volatile
Interest Income1.8 M1.7 M784.9 K
Pretty Stable
Reconciled Depreciation840 K800 K195.9 K
Slightly volatile
Selling And Marketing Expenses12.2 M18.4 M4.9 M
Slightly volatile

Fennec Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow10.8 M13.3 M11.7 M
Slightly volatile
End Period Cash Flow28 M26.6 M14 M
Slightly volatile
Stock Based Compensation5.3 M5.1 M2.2 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio3.453.6286596.3 K
Slightly volatile
Days Sales Outstanding93.9898.92421 M
Slightly volatile
Average Payables1 M1.4 M1.5 M
Pretty Stable
Stock Based Compensation To Revenue0.10.106511.6736
Slightly volatile
Capex To Depreciation0.09990.110.1263
Slightly volatile
EV To Sales3.33.4752591.4 K
Slightly volatile
Sales General And Administrative To Revenue0.460.484952.612
Slightly volatile
Average Inventory226.8 K216 K222.7 K
Slightly volatile
Research And Ddevelopement To Revenue0.00610.006586.9 K
Slightly volatile
Capex To Revenue474.3 K451.7 K468.6 K
Slightly volatile
Cash Per Share0.930.97580.6955
Slightly volatile
Intangibles To Total Assets0.440.540.5801
Pretty Stable
Current Ratio5.116.37726.3326
Slightly volatile
Receivables Turnover3.873.68971.3388
Slightly volatile
Capex Per Share0.00530.00560.0084
Slightly volatile
Average Receivables120.4 K92.4 K87.2 K
Very volatile
Revenue Per Share1.831.74170.2847
Slightly volatile
Interest Debt Per Share0.90.85770.3451
Slightly volatile
Debt To Assets0.380.43030.3392
Slightly volatile
Operating Cycle2092201 M
Slightly volatile
Long Term Debt To Capitalization0.771.43610.4989
Slightly volatile
Total Debt To Capitalization1.511.4360.554
Slightly volatile
Quick Ratio5.066.2246.2942
Slightly volatile
Net Income Per E B T5.85.535.7552
Slightly volatile
Cash Ratio4.423.84946.304
Slightly volatile
Days Of Sales Outstanding93.9898.92421 M
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.131.151.0203
Slightly volatile
Fixed Asset Turnover0.00.00.0
Slightly volatile
Debt Ratio0.380.43030.3392
Slightly volatile
Price Sales Ratio3.453.6286596.3 K
Slightly volatile
Asset Turnover1.111.05770.1951
Slightly volatile
Gross Profit Margin0.890.9335.2 K
Slightly volatile

Fennec Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap145.6 M131.6 M135.3 M
Slightly volatile
Enterprise Value121.1 M113.1 M112.5 M
Slightly volatile

Fennec Fundamental Market Drivers

Forward Price Earnings12.0048
Cash And Short Term Investments26.6 M

Fennec Upcoming Events

4th of April 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Fennec Pharmaceuticals Financial Statements

Fennec Pharmaceuticals stakeholders use historical fundamental indicators, such as Fennec Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Although Fennec Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Fennec Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Fennec Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Fennec Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue248 K260.4 K
Total Revenue47.5 M49.9 M
Cost Of Revenue3.2 M3.3 M
Stock Based Compensation To Revenue 0.11  0.10 
Sales General And Administrative To Revenue 0.48  0.46 
Research And Ddevelopement To Revenue 0.01  0.01 
Capex To Revenue451.7 K474.3 K
Revenue Per Share 1.74  1.83 
Ebit Per Revenue 0.05  0.06 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
DDDupont De Nemours
CRDOCredo Technology Group
GOOGAlphabet Inc Class C
When determining whether Fennec Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Fennec Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Fennec Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Fennec Pharmaceuticals Stock:
How To Invest In Fennec
Details
Is Fennec Stock a good investment?
Details
What is Fennec Pharmaceuticals' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Fennec Pharmaceuticals Correlation against competitors.
For information on how to trade Fennec Stock refer to our How to Trade Fennec Stock guide.
You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fennec Pharmaceuticals. If investors know Fennec will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fennec Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.26)
Revenue Per Share
1.408
Quarterly Revenue Growth
0.787
Return On Assets
(0.05)
Return On Equity
(10.06)
The market value of Fennec Pharmaceuticals is measured differently than its book value, which is the value of Fennec that is recorded on the company's balance sheet. Investors also form their own opinion of Fennec Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Fennec Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fennec Pharmaceuticals' market value can be influenced by many factors that don't directly affect Fennec Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Fennec Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fennec Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fennec Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY